China India Russia covid-19 testing patient China India Russia

India’s CDRI gets approval for Phase III trial of Umifenovir to treat Covid-19

Reading now: 392
www.pharmaceutical-technology.com

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Central Drug Research Institute (CDRI), a constituent lab of India-based Council of Scientific and Industrial Research (CSIR), has secured approval for carrying out Phase III trial for the use of Umifenovir in the treatment of Covid-19.

In this randomised, double-blind, placebo-controlled trial, CDRI will test the efficacy, safety and tolerability of  Umifenovir.

According to a statement by the government: “This drug has a good safety profile and acts by preventing entry of virus into human cells and also by priming the immune system.” Umifenovir is a drug primarily used to treat influenza.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA